Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acquired | Acquired

Total Raised


About Jiangyin Tianjiang Pharmaceutical

Provider of concentrated traditional Chinese medicine (TCM) granules. The company produces approximately 700 types of single-herb concentrated granules. It also offers original equipment manufacturing services, including medicine extraction, processing, granulation, and packaging.

Jiangyin Tianjiang Pharmaceutical Headquarters Location

1 Xinsheng Road

Jiangyin, Jiangsu, 214434,


86 510 86405629

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Jiangyin Tianjiang Pharmaceutical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Jiangyin Tianjiang Pharmaceutical is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Jiangyin Tianjiang Pharmaceutical News

Efficacy of the Jingxin Zhidong Formula for Tic Disorders: A Randomized, Double Blind, Double Dummy, Parallel Controlled Trial

Jan 10, 2022

Fei Fan,1 Long Hao,2 Si Zhang,1 Ying Zhang,3 Zhaoxiang Bian,4 Xuan Zhang,4 Qiong Wang,5 Fei Han1 1Department of Paediatrics, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of China; 2Department of Paediatrics, Beijing Fangshan District Liangxiang Hospital, Beijing, People’s Republic of China; 3Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 4Chinese EQUATOR Centre, Hong Kong Chinese Medicine Clinical Study Centre, Chinese Clinical Trial Registry (Hong Kong), School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong, People’s Republic of China; 5Clinical Medical School, Beijing University of Chinese Medicine, Beijing, People’s Republic of China Correspondence: Fei Han Department of Paediatrics, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, No. 5, Beixiange Road, Xicheng District, Beijing, 100053, People’s Republic of China Tel +86 10-8800 1128 Background: The Jingxin Zhidong formula (JXZDF), a traditional Chinese medicine, has been widely used to treat tic disorder (TD) in China. However, its efficacy has not yet been evaluated in a randomized controlled trial. We aimed to compare the effectiveness and safety of JXZDF and aripiprazole in patients with TD. Methods: In this randomized, double-blind, double-dummy, parallel controlled trial, 120 patients with TD, aged 6– 16 years were randomly assigned to receive either JXZDF (n = 60, 17.6 g/day) or aripiprazole (n = 60, 10 mg/day) for 12 weeks. The primary outcome was measured using the Yale Global Tic Severity Scale (YGTSS). Adverse events were assessed using the Treatment Emergent Symptom Scale. Results: JXZDF produced greater improvements than aripiprazole in the following YGTSS subscale scores at the endpoint: total tic scores (P = 0.004, 95% CI: 1.085– 3.494) and total motor scores (P = 0.004, 95% CI: 0.313– 1.739). The difference in rate between the groups was no significant (χ2 = 0.702, degrees of freedom = 1, P = 0.402). The overall incidence of adverse events was significantly lower in the JXZDF group than in the aripiprazole group (0% vs 6.67%, P Conclusion: JXZDF had a better safety profile than aripiprazole, and it was not inferior in terms of clinical efficacy. JXZDF warrants consideration as a potential treatment option for TD. Trial Registration: CHiCTR, ChiCTR2000039601 (Registered November 2, 2020). Keywords: tic disorder, Tourette syndrome, Chinese herbal Medicine formula, randomized controlled trial, Jingxin Zhidong formula Background Tic disorder (TD) is a group of childhood-onset neuropsychiatric disorders defined by the presence of one or more motor and/or phonic tics, which are characterised by sudden, rapid, recurrent, non-rhythmic motor movements or vocalisations. 1 According to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5, 2 TD includes Tourette’s disorder, persistent (chronic) motor or vocal TD, provisional TD (referred to as transient TD in the DSM-IV), unspecified TD and other specified TD. Current studies have shown that the pathophysiology of TD mainly includes immunological, genetic, neurobiochemical, and inflammation-related processes. 1 TD frequently co-occurs with various behavioural complications, including attention-deficit hyperactivity disorder (ADHD), obsessive-compulsive behaviour, and obsessive-compulsive disorder (OCD); 3 these conditions have severe effects on the quality of life of patients and their ability to work, resulting in a significant financial burden. For patients with TD, medical education and psychological support are the first-line treatments. Atypical antipsychotic medications, such as aripiprazole and risperidone, are the preferred pharmacological treatments, because psychological interventions are not effective or available for all patients. 4 However, these drugs are often associated with adverse effects, such as sedation, weight gain, cognitive dulling, and adverse motor effects. 5 , 6 Therefore, alternative therapeutic strategies with equivalent efficacy and superior safety profiles are needed. Traditional Chinese medicines (TCMs), as alternative therapies, have been increasingly used to treat TD in the past decade. Several trials have suggested that TCMs possess therapeutic potential against TD. 7 , 8 , 10 Jingxin Zhidong formula (JXZDF) is an individualised TCM formula pioneered by Prof. Fei Han, a famous Chinese paediatrician. It originates from the therapy theory of tranquilizing mind by nourishing the heart and calming the liver wind. 8 JXZDF comprises 13 herbal medicines: Zhenzhumu (Concha Margaritifera), calcined Longgu (Os Draconis), Muli (Concha Ostreae), Suan zao ren (Semen Ziziphi Spinosae), Baiziren (Semen Platycladi), Baishao (Radix Paeoniae Alba), Jiangcan (Bombyx Batryticatus), Chaihu (Radix Bupleuri), Niubangzi (Fructus Arctii), Zhiqiao (Fructus Aurantii), Dilong (Lumbricus), Chantui (Periostracum Cicadae), and Baizhi (Angelica Dahurica). These herbs are widely used in the treatment of neuropsychiatric diseases. 9–15 In TCM practice, drugs containing Bombyx Batryticatus have been used to treat convulsions, 12 and Os Draconis, Concha Ostreae, and Radix Bupleuri have been used to relieve epileptic symptoms. 9 All of the above evidence suggests that these herbs might be potentially effective against tics. The choice of herbal medicine is in accordance with the traditional Chinese medicinal theories on the use of herbs. JXZDF has been Clinically used to treat TD for decades in Guang’anmen Hospital, China Academy of Chinese Medical Sciences (Beijing, China). However, its efficacy has not yet been evaluated in a randomized controlled trial. In this study, we aimed to evaluate the efficacy and safety of pre-made JXZDF granules in children (6–16 years old) with TD. Methods Aim The aim of this study was to investigate the efficacy of JXZDF in alleviating TD symptoms and the related impairments. Trial Design and Setting This was a randomized, double blind, double dummy, parallel controlled trial. It was conducted in the Department of Paediatrics, Guang’anmen Hospital, China Academy of Chinese Medical Sciences. Recruitment Patients were recruited between January 2014 and December 2015. All children were outpatients in the Department of Paediatrics of Guang’anmen Hospital and were recruited after study advertisement. Eligibility Criteria Inclusion Criteria The inclusion criteria were as follows: (1) aged 6–16 years; (2) diagnosis of TD (DSM-V); (3) Yale Global Tic Severity Scale (YGTSS) 16 scores of more than 25 points at the time of screening. Exclusion Criteria The exclusion criteria were as follows: (1) principal diagnosis of ADHD, OCD, Wilson disease, Huntington’s disease, rheumatic chorea, epilepsy, intellectual disability, or schizophrenia; (2) tics caused by medications or an undetermined cause; (3) intracranial space-occupying lesions or serious comorbid cardiac, hepatic or renal conditions; (4) a history of allergic reactions to drugs used in this trial; (5) laboratory detection values of hepatic and renal functions that considerably exceeded the normal reference ranges; (6) severe abnormalities detected via electrocardiogram or electroencephalogram tests; and (7) current participation in other clinical trials involving pharmaceutical interventions. Interventions Preparation of Study Medications JXZDF and placebo granules were prepared by Jiangyin Tianjiang Pharmaceutical Co. Ltd in strict compliance with the standards of good manufacturing practice. Quality control and assurance were performed by the manufacturer. 17 A sample specimen has been maintained in the Department of Paediatrics, Guang’anmen Hospital, China Academy of Chinese Medical Sciences. As shown in Table 1 , JXZDF contains 13 ingredients, and the quality of these herbs and decoction preparation was in accordance with the Chinese Pharmacopoeia (2005). All ingredients were mixed in appropriate proportions and dissolved in distilled water for 1 h at room temperature (18°C–26°C). Decoction (1 h duration) was performed two times. The decoction obtained was condensed and dried at 60°C in a vacuum dryer to produce a granule formation. The granules were packaged in small sachets (each weighing 8.8 g) and stored at room temperature (18°C–26°C) before use. Samples of JXZDF placebo granules were tested for microbial contamination and deposited with the manufacturer for traceability. The placebo granules were prepared to be identical to JXZDF granules and active aripiprazole in terms of appearance, odour, and colour; they were prepared with dextrin, and food colour and aqueous citric acid were used to mimic the odour and colour of JXZDF. Each aripiprazole tablet (Zhejiang Otzuka Pharmaceutical Co., Ltd., batch number: H20041507) contained 5 mg of the active ingredient. All study medications were packaged by the Pharmacy Department of Guang’anmen Hospital. Table 1 Components of the Jingxin Zhidong Formula Study Design This was a 12-week, randomized, double-blind clinical trial that involved 12 weeks of therapy and three follow-up visits every 4 weeks. Patients were randomized to receive either orally administered JXZDF (8.8 g, twice daily) plus aripiprazole placebo tablets (5 mg, twice daily) or aripiprazole (5 mg, twice daily) plus JXZDF placebo granules (8.8 g, twice daily). No other medications were administered to the patients during the treatment period. The following assessments were made before patient inclusion: routine blood and urine tests; evaluation of liver and kidney functions; electrocardiogram assessment; documentation of medical history; and physical and neurological examinations. A flow chart of this study is shown in Table 2 . Table 2 Trial Flow Chart Adherence To improve the validity of data, medication compliance was assessed using a variety of methods, including TCM packet counts and weekly telephone follow-up, asking participants whether they were taking the appropriate medication and the reasons for not taking the medication. The participants were asked to return the unused drugs after 12 weeks. We maintained the statistics and records of the participants. Concomitant Care For 12 weeks, the participants were not allowed to use other TCM or western drugs for TD because these drugs could be confused with the effects of JXZDF. Outcome Measurements The primary outcome was measured using the YGTSS and its subscales: total motor (YM) scores (0–25), total phonic (YP) scores (0–25), total tic (YT) scores (sum of YM and YP scores), and tic-related impairment (YI) scores (0–50). The YGTSS has been previously validated in studies conducted among patients with TD. The YGTSS score is the sum of the YT and YI scores. The primary endpoint was the reduction in the YGTSS score and its subscales after 12 weeks of therapy relative to those at baseline. Clinical recovery was indicated by a ≥80% reduction in the YGTSS score, whereas significant improvement was indicated by a reduction of ≥50% and <80%. The treatment was considered to be effective if the YGTSS score reduction was ≥30% and <50%, whereas it was considered ineffective if the YGTSS score reduction was <30%. Adverse events were assessed at each visit using the Treatment Emergent Symptom Scale, 18 which included the most commonly encountered adverse effects of aripiprazole and TCM herbs. At the end of the study, physical examinations, blood and urine tests, liver and kidney function evaluations, and electrocardiogram assessments were repeated. All tests were conducted by a single examiner who was blinded to the study outcomes and treatment allocation. Sample Size Calculation In this trial, the effective ratio of JXZDF and aripiprazole was 80% and 83.3%, with α = 0.05, β = 0.2, a target power = 0.8, and an estimated sample size = 598. 19 However, owing to limited research funds and the fact that this was a single-centre study, the number of outpatients could not meet the demand of the sample size; only 120 patients were included in the study. Randomisation and Blinding Patients who met the inclusion criteria were assigned to the JXZDF group or the aripiprazole group at a ratio of 1:1 using the PROC PLAN program of SAS package (SAS for Windows, Version 6.12, SAS Institute Inc., Cary, NC). The trial medications were packed in boxes marked with random numbers, and the appearance of all packages was identical. The random codes designating group allocation were sealed in opaque envelopes and kept by the Clinical Efficacy Evaluation Centre of Guang’anmen Hospital, China Academy of Chinese Medical Sciences, which was not associated with the investigator’s team. Participants, investigators, and personnel responsible for data entry and analysis were all blinded to group allocation. Statistical Analyses The demographic and clinical characteristics of the patients are presented as mean, standard deviation, and 95% confidence interval [CI]. Normality of the data was tested using the Shapiro–Wilk test. Comparisons between groups were made using the independent sample t-test and repeated measures analysis of variance (ANOVA), provided that the data were normally distributed. Otherwise, Wilcoxon rank-sum test was used as the alternative method. Categorical data were compared using the χ2 test or Fisher’s exact test. Simple-effects analyses were performed when we observed an interaction, otherwise we observed main effects. Statistical significance was defined as two-tailed p < 0.05. According to the intent-to-treat principles, the last observation was used for patients whose data were not observed throughout the study for statistical estimation and making inferences. 20 In this study, missing data were calculated using the regression imputation method. All statistical analyses were conducted using SPSS software program (SPSS for Windows, Version 19.0. Chicago, SPSS Inc.). Ethical Considerations This randomized controlled trial was retrospectively registered at the Chinese Clinical Trial Registry (ChiCTR2000039601; November 2, 2020). The study protocol was approved by the Ethics Committee of the China Academy of Chinese Medical Sciences Guang’anmen Hospital and conducted in accordance with the World Medical Association Declaration of Helsinki. 21 , 22 The primary guardians of all enrolled children provided written informed consent; written consent was also obtained from children over 8 years of age. The sample size and all outcome measures were determined before study initiation and were not modified thereafter. Results Participant Characteristics A total of 632 patients with TD were screened between January 2014 and December 2015; 175 patients met the inclusion criteria and had YGTSS scores of 25–70 at the time of screening. Among these patients, 120 agreed to participate in the trial. There were 60 patients in each group. Their average age was 9.23 ± 2.60 years, and 108 of the patients were males (90%). The median duration of illness was 24 (interquartile range, 12–36) months. There were no significant differences in age, sex ratio, or duration of illness between the treatment groups. A total of 109 (90.8%) patients completed the 12-week treatment period, whereas 11 patients discontinued treatment due to intolerable adverse effects (n = 2); loss to follow-up (n = 7), that is, inability to return for follow-up and emigration; and personal reasons, which the patients refused to disclose (n = 2) ( Figure 1 ). The baseline characteristics and assessment scores of the patients are summarised in Table 3 . There were no significant differences in baseline variables between the groups. Table 3 Baseline Characteristics of Patients with TD Figure 1 Flowchart of patient screening and recruitment. Abbreviation: JXZDF, Jingxin Zhidong formula. Comparison of Treatment Outcomes Between the Groups The treatment outcomes are summarised in Table 4 . There were no significant differences in the assessment scores between the groups at baseline. Throughout the intervention period, the YT ( Figure 2 ), YM ( Figure 3 ), YP ( Figure 4 ), and YI ( Figure 5 ) scores decreased in both groups at each follow-up assessment. The YT ( Figure 2 ) and YM ( Figure 3 ) scores were lower in the JXDZF group than in the aripiprazole group at week 12. Both YT and YM scores were significant differences between the groups at week 12 ( Supplementary Tables 1 – 6 ) However, no significant differences were observed between the groups at week 4 or week 8. Table 4 Treatment Outcomes Measured Using the YGTSS in Patients with TD Figure 2 Yale Global Tic Severity Scale YT scores from baseline to the endpoint. The YT score was significantly lower in the JXZDF group than in the aripiprazole group at week 12, p = 0.004 (1.085–3.494). Abbreviations: JXZDF, Jingxin Zhidong formula; YT, total tic. Figure 3 Yale Global Tic Severity Scale YM scores from baseline to the endpoint. The YM score is significantly lower in the JXZDF group than in the aripiprazole group at week 12, p = 0.004 (0.313–1.739). Abbreviations: JXZDF, Jingxin Zhidong formula; YM, total motor. Figure 4 Yale Global Tic Severity Scale YP scores from baseline to the endpoint. Abbreviations: JXZDF, Jingxin Zhidong formula; YP, total phonic. Figure 5 Yale Global Tic Severity Scale YI scores from baseline to the endpoint. Abbreviations: JXZDF, Jingxin Zhidong formula; YI, impairment. Clinical recovery or significant improvement was observed in 93.3% (56/60) of JXZDF-treated patients; this did not differ significantly from the aripiprazole-treated patients (96.7%, 58/60; χ2 = 0.702, degrees of freedom = 1, p = 0.402). Adverse Events The incidence of adverse events in the two groups is summarised in Table 5 . In the aripiprazole group, four (6.67%) patients experienced adverse events, including dizziness (n = 1; dose = 5 mg/day), stomachache (n = 2; dose = 5 mg/day), and sleepiness (n = 1; dose = 5 mg/day); these resulted in the drop out of two (3.33%) patients. No adverse events were observed in the JXZDF group. The incidence of adverse events was significantly different between the groups (p < 0.001). Table 5 Incidence of Major Adverse Events in the Two Groups of Patients with Tic Disorders Discussion According to TCM theory, TD is most related to “wind syndromes”, which are characterized by vertigo, sleep disorders, musculoskeletal paralysis, pruritus, tremor, numbness, and spasm; mainly caused by the lack of spirit preservation and liver wind agitation. 23 Tranquilizing the mind by nourishing the heart and calming the liver can alleviate the “wind syndromes” according to Huangdi Neijing (Yellow Emperor’s Canon) by the Yellow Emperor of China (2695–2589 BC). Considering the physiological and pathological characteristics of children, mind-soothing and liver wind-extinguishing medicines were selected to alleviate tic symptoms in this study. The results of this study showed that JZXDF was effective in the treatment of TD. The prevalence of TD across China is 6.1%. 24 Behavioural therapy 25 and deep brain stimulation 26 can also be used to treat TD; however, they are not suitable for all patients owing to their high cost and limited applicability to specific disease conditions. In recent years, several studies have demonstrated the efficacy of traditional Chinese herbal medicines in the treatment of psychiatric disorders 27 , 28 and explored their potential mechanisms. 9–15 JXZDF is an individualised TCM formula and has been clinically used to treat TD for decades in China, and it is considered safe and effective. Although both groups of patients in the present study showed improvements in motor and vocal tics during the treatment, patients in the JXZDF group exhibited significantly lower YT scores and YM subscale scores than those in the aripiprazole group. The proportion of patients in the JXZDF group who achieved a clinical response at week 12 was not statistically different from that in the aripiprazole group. JXZDF was safer than aripiprazole, and fewer patients in the JXZDF group withdrew from this trial. TD has a multifactorial aetiology and multi-system pathogenesis. The dysfunction of neurotransmitters (eg, dopamine, glutamate, γ-aminobutyric acid, 5-hydroxytryptamine, and noradrenaline) in the cortico-striato-thalamo-cortical circuits contributes to TD development. 1 Among the ingredients in the JXZDF formulation, Radix Bupleuri, Os Draconis, and Concha Ostreae are known to relieve disorders by clearing away heat, tranquilizing the mind, and eliminating excitement. 9 Several studies have suggested that components derived from these three herbal materials are potentially effective for treating psychiatric disorders, including epilepsy and insomnia. 29 The active components of Radix Bupleuri and Radix Paeoniae Alba can increase plasma adrenocorticotropic hormone levels and decrease 5-hydroxytryptamine and dopamine levels. 30 Semen Ziziphi Spinosae modulates the levels of monoamines and amino acid neurotransmitters in the brain. 31 Furthermore, extracts from Bombyx Batryticatus and Lumbricus possess broad psychotherapeutic properties, as they modulate brain γ-aminobutyric acid, glutamate, and related glutamate receptor activities. 14 , 32 Therefore, the efficacy of JXZDF observed in this study might be related to a variety of pharmacological and therapeutic properties of these components. Furthermore, the associations between gut microbiota and neuropsychiatric diseases has received increasing research attention, known as the gut–brain axis. Both clinial and animal studies demonstrated that microbiota have the potential to improve tic syndromes. 33–35 Notably, several components of the JXZDF, including Semen Ziziphi Spinosae, Radix Bupleuri, Fructus Aurantii and Angelica Dahurica are potentially effective at modulating gut microbiota abundances. 36–39 Further studies could be designed to assess the gut microbiota to reveal the underlying pharmacological and therapeutic effects of JXZDF for the treatment of TD. Limitations The present study had some limitations. First, due to limited funding, the number of enrolled patients was inadequate; this might have reduced the precision of the results. Nevertheless, significant differences in the outcomes were observed between the JXZDF and aripiprazole groups. Second, differences in the population, including height, weight, genetics, co-occurring behavioural complications, and dietary factors, were not analysed in this study. Moreover, the randomisation method did not consider that the participants in the JXDZF group were slightly older; this is a possible confounding factor. Third, the dosage of the two medications was not adjusted according to the specific clinical conditions of each patient. In general, the initial dose of aripiprazole for children is 2 mg/day, which can be titrated up to 10 mg/day, depending on disease severity. 40 In this study, we used the maximum dose of aripiprazole recommended for children. This may have resulted in a more rapid efficacy, earlier resistance, and relatively significant adverse effects in the aripiprazole group. In contrast, resistance was not observed in the JXZDF group. This may account for the difference in efficacy between the groups at week 12. Fourth, this trial involved only 12 weeks of therapy, with a lack of information on the effectiveness and safety of longer JXZDF treatments. Fifth, this study was a single-centre trial, and only children (aged 6–16 years) were included in this study owing to the study setting of the Department of Paediatrics; further studies are needed to determine the effects of JXZDF on adults. Sixth, this trial lacked an inactive placebo, and the effects observed in both groups could be solely due to the placebo effect. Finally, syndrome differentiation of TCMs was not considered in the present study. Therefore, additional studies are needed to determine whether JXZDF is more beneficial for specific TCM syndrome types. Conclusions The results of this study suggest that JXZDF is non-inferior to aripiprazole in terms of its effectiveness to alleviate tic symptoms and the related impairments. However, we demonstrated that JXZDF has a better safety profile. Therefore, JXZDF warrants consideration as a potential therapy for TD. Acknowledgments

  • Where is Jiangyin Tianjiang Pharmaceutical's headquarters?

    Jiangyin Tianjiang Pharmaceutical's headquarters is located at 1 Xinsheng Road, Jiangyin.

  • What is Jiangyin Tianjiang Pharmaceutical's latest funding round?

    Jiangyin Tianjiang Pharmaceutical's latest funding round is Acquired.

  • How much did Jiangyin Tianjiang Pharmaceutical raise?

    Jiangyin Tianjiang Pharmaceutical raised a total of $4.98M.

  • Who are the investors of Jiangyin Tianjiang Pharmaceutical?

    Investors of Jiangyin Tianjiang Pharmaceutical include China International Capital Corporation and Homsun Capital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.